Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.
Latest from Jessica Merrill
Chris Boshoff has been with Pfizer more than 10 years and has led oncology R&D and the integration of Seagen. He will succeed Mikael Dolsten, who will depart after leading R&D for nearly 15 years.
The new formulation is expected to play a role in helping Merck maintain its multibillion-dollar cancer franchise after Keytruda loses exclusivity in 2028.
The company has reached agreement with the US FDA on a pivotal trial for RGX-202 through an accelerated pathway.
The company will in-license LM-299, gaining a PD-1/VEGF bispecific antibody that could help it defend its blockbuster PD-1 franchise against looming competition.
The MEK inhibitor, already approved for pediatric patients with the rare condition neurofibromatosis type 1, showed benefits for adults in a Phase III trial.
The company said it does not see a development path for zelnecirnon based on feedback from the US FDA. It halted two Phase II trials in asthma and atopic dermatitis earlier this year.